Papp Kim A
Probity Medical Research, Waterloo, Ontario, Canada.
Drugs Today (Barc). 2004 Nov;40(11):889-99. doi: 10.1358/dot.2004.40.11.872578.
Recent research has demonstrated that psoriasis is not the result of a keratinocyte disorder, as previously believed. Although the exact etiology has not been clearly defined, much data has accumulated to elucidate the role of the immune system, particularly T lymphocytes, in the pathogenesis of the disease. With this knowledge, a number of biologic therapies that specifically target key pathogenic events have been developed. Efalizumab, a recombinant humanized monoclonal IgG1 antibody, is a T-cell modulator approved for patients with moderate to severe chronic plaque psoriasis. This article reviews the role of T lymphocytes in psoriasis pathogenesis, the mechanism of efalizumab action, and the efficacy and safety data observed during the efalizumab clinical trials.
最近的研究表明，银屑病并非如之前所认为的那样是角质形成细胞紊乱的结果。尽管确切病因尚未明确界定，但已有大量数据积累，以阐明免疫系统，尤其是T淋巴细胞在该疾病发病机制中的作用。基于这一认识，已开发出多种专门针对关键致病事件的生物疗法。依法利珠单抗是一种重组人源化单克隆IgG1抗体，是一种被批准用于治疗中度至重度慢性斑块状银屑病患者的T细胞调节剂。本文综述了T淋巴细胞在银屑病发病机制中的作用、依法利珠单抗的作用机制以及在依法利珠单抗临床试验期间观察到的疗效和安全性数据。
